Kaleido Stock Analysis

KLDO -  USA Stock  

USD 6.73  0.03  0.44%

The big decline in price over the last few months for Kaleido Biosciencesmay raise some interest from institutional investors. The stock closed today at a share price of 6.73 on 387,600 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Kaleido Biosciences or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.38. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kaleido Biosciences partners.
Please see Stocks Correlation.

Search Stock Analysis 

The Kaleido Biosciences stock analysis report makes it easy to digest most publicly released information about Kaleido Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kaleido stock analysis module also helps to analyze the Kaleido Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Kaleido Stock Analysis Notes

About 81.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.44. Kaleido Biosciences had not issued any dividends in recent years. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Kaleido Biosciences contact Mike Bonney at 617 674 9000 or learn more at http://kaleido.com.

Kaleido Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kaleido Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kaleido Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kaleido Biosciences generates negative expected return over the last 90 days
Kaleido Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (85.11 M) with loss before overhead, payroll, taxes, and interest of (54.99 M).
Kaleido Biosciences currently holds about 92.36 M in cash with (67.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.17.
Kaleido Biosciences has a frail financial position based on the latest SEC disclosures
Over 81.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Kaleido Biosciences Inc gains 1.3330 percent for June 14 - Equities.com

Kaleido Biosciences Upcoming and Recent Events

Earnings reports are used by Kaleido Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kaleido Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of August 2021
Next Earnings Report1st of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End2nd of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Kaleido Largest EPS Surprises

Earnings surprises can significantly impact Kaleido Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Kaleido Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kaleido Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kaleido Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kaleido Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
17th of June 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
4th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
24th of March 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
3rd of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of February 2021
Unclassified Corporate Event
10th of February 2021
Unclassified Corporate Event
8th of February 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
25th of January 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Kaleido Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kaleido Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kaleido Biosciences backward and forwards among themselves. Kaleido Biosciences' institutional investor refers to the entity that pools money to purchase Kaleido Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Flagship Pioneering IncCommon Shares19.6 M158.6 M
Fmr LlcCommon Shares6.4 M51.6 M
Harbourvest Partners LlcCommon Shares1.8 M14.9 M
Blackrock IncCommon SharesM8.2 M
Vanguard Group IncCommon Shares986.2 KM
Federated Hermes IncCommon Shares825 K6.7 M
Palo Alto Investors LpCommon Shares786.4 K6.4 M
Note, although Kaleido Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kaleido Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 287.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kaleido Biosciences's market, we take the total number of its shares issued and multiply it by Kaleido Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Kaleido Profitablity

Kaleido Biosciences' profitability indicators refer to fundamental financial ratios that showcase Kaleido Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Kaleido Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kaleido Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kaleido Biosciences' profitability requires more research than a typical breakdown of Kaleido Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(1.14) (1.23) 
Return on Average Equity(2.31) (2.37) 
Return on Invested Capital(3.77) (4.07) 
Return on Sales(72.76) (78.50) 

Management Efficiency

The entity has return on total asset (ROA) of (59.77) % which means that it has lost $59.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (161.51) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences management efficiency ratios could be used to measure how well kaleido biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.23. The value of Return on Average Equity is estimated to slide to -2.37. Kaleido Biosciences Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 68.54 Million. Current Assets is expected to rise to about 58.5 M this year, although the value of Assets Non Current will most likely fall to about 10.1 M.
Last ReportedProjected for 2021
Book Value per Share 0.61  0.66 
Enterprise Value over EBIT(4.00) (4.11) 
Enterprise Value over EBITDA(3.79) (4.09) 
Price to Book Value 15.98  13.92 
Tangible Assets Book Value per Share 1.77  1.82 
Enterprise Value291.6 M261.7 M
Tangible Asset Value59.3 M68.5 M

Technical Drivers

As of the 19th of June, Kaleido Biosciences secures the mean deviation of 4.98, and Risk Adjusted Performance of (0.036373). Kaleido Biosciences technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down nineteen technical drivers for Kaleido Biosciences, which can be compared to its peers in the industry. Please verify Kaleido Biosciences coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Kaleido Biosciences is priced some-what accurately, providing market reflects its recent price of 6.73 per share. Given that Kaleido Biosciences has jensen alpha of (0.41), we recommend you to check Kaleido Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.

Kaleido Biosciences Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Mid-point over period is an average of Kaleido Biosciences highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Kaleido Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kaleido Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kaleido Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kaleido Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Hylckama Vlieg Johan over a month ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over three months ago via Macroaxis 
Acquisition by Jerald Korn of 60000 shares of Kaleido Biosciences subject to Rule 16b-3
Menichella Daniel L over three months ago via Macroaxis 
Purchase by Menichella Daniel L of 20000 shares of Kaleido Biosciences
Flagship Ventures Fund Iv General Partner Llc over three months ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over six months ago via Macroaxis 
Acquisition by Jerald Korn of 45000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over six months ago via Macroaxis 
Acquisition by Prener Anne of 15000 shares of Kaleido Biosciences subject to Rule 16b-3
Nutritional Health Ltp Fund General Partner Llc over a year ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Melas Kyriazi Theo over a year ago via Macroaxis 
Purchase by Melas Kyriazi Theo of 33333 shares of Kaleido Biosciences
Jerald Korn over a year ago via Macroaxis 
Acquisition by Jerald Korn of 45000 shares of Kaleido Biosciences subject to Rule 16b-3
Duke William E over a year ago via Macroaxis 
Acquisition by Duke William E of 50000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over a year ago via Macroaxis 
Acquisition by Prener Anne of 30000 shares of Kaleido Biosciences subject to Rule 16b-3
Jerald Korn over a year ago via Macroaxis 
Acquisition by Jerald Korn of 6563 shares of Kaleido Biosciences subject to Rule 16b-3

Kaleido Biosciences Predictive Daily Indicators

Kaleido Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kaleido Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kaleido Biosciences Forecast Models

Kaleido Biosciences time-series forecasting models is one of many Kaleido Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kaleido Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Kaleido Biosciences Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kaleido Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kaleido shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Kaleido Biosciences. By using and applying Kaleido Stock analysis, traders can create a robust methodology for identifying Kaleido entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(71.07) (76.68) 
Gross Margin 0.90  0.89 
Profit Margin(75.34) (81.29) 
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Current Kaleido Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kaleido analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kaleido analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Kaleido Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kaleido analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kaleido stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kaleido Biosciences, talking to its executives and customers, or listening to Kaleido conference calls.
Kaleido Analyst Advice Details

Kaleido Stock Analysis Indicators

Kaleido Biosciences stock analysis indicators help investors evaluate how Kaleido Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kaleido Biosciences shares will generate the highest return on investment. By understating and applying Kaleido Biosciences stock analysis, traders can identify Kaleido Biosciences position entry and exit signals to maximize returns.
Quick Ratio7.18
Fifty Two Week Low5.04
Shares Short Prior Month2.81M
Average Daily Volume Last 10 Day147.6k
Average Daily Volume In Three Month274.09k
Shares Percent Shares Out7.65%
Short Percent Of Float15.54%
Forward Price Earnings-3.10
Float Shares20.94M
Fifty Two Week High20.50
Enterprise Value To Ebitda-2.75
Fifty Day Average7.04
Two Hundred Day Average9.11
Enterprise Value To Revenue173.02
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Kaleido Biosciences Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.